CAR-T Cell Therapy Market - Global Growth, Trends and Forecast (2022 - 2027) By Types, By Application, By Regions, and By Key Players: Novartis AG (SWX: NOVN), Amgen Inc. (NASDAQ: AMGN), Fate Therapeutics (NASDAQ: FATE, Pfizer Inc. (NYSE: PFE)

Registering a CAGR of 31.5% over the forecast period, the market value of CAR-T Cell Therapy is expected to reach US$ 19,566.5million in the year 2027.

CAR-T Cell Therapy Market Overview

Chimeric antigen receptor (CAR) T-cell therapy is a method of obtaining immune cells known as T cells. CAR T-cell therapy aids in the treatment of certain lymphomas and leukemias, as well as multiple myeloma. Many clinical trials for CAR T-cell therapies are being conducted around the world in order to expand cancer treatment options.

The growing awareness of cell-based therapies and their benefits in treating various types of diseases and disorders has increased cell-based therapy research and development activities, resulting in an increase in the number of clinical trials worldwide. Furthermore, many people are eager to enroll in clinical studies, particularly those involving CAR-T cell therapy, fueling market growth through 2027.

Going forward, the market is expected to be driven by an increase in the incidence rate of blood cancer, an increase in healthcare expenditure, a strong pipeline of drugs, and a growing focus on cart therapy. High therapy costs, reimbursement challenges, adverse events, complex manufacturing, supply chain and covid-19 impacting drug trials, and a reduction in free trade are all major factors that could stymie future CAR-T therapy market growth. The increased emphasis on cancer research and development therapies, such as lung cancer, colorectal cancer, multiple myeloma cancer, and prostate cancer, is expected to create significant growth opportunities for CAR T-cell therapy providers. Acquisitions can also significantly accelerate a manufacturer's strategy to capitalize and capture a sizable market share.

The report aspects discussed the profile of the top manufacturers of the global CAR-T Cell Therapy market. These aspects include the financial status of major companies, trending advancements, and the entire market scenario. Growth of the report has examined CAR-T Cell Therapy Market production, demand and growth potential, geographic analysis, as well as current market developments in various regions and countries.

Who are the Major Players in the CAR-T Cell Therapy Market?

The global CAR-T Cell Therapy includes the identification and analysis of the various market participants competing in the global market. Prominent competitors include Novartis AG (SWX: NOVN), McKinsey & Company, Bristol-Myers Squibb Company (NYSE: BMY), Gilead Sciences, Inc. (NASDAQ: GILD), Amgen Inc. (NASDAQ: AMGN), Juno Therapeutics, Eli Lilly and Company (NYSE: LLY), Fate Therapeutics (NASDAQ: FATE), Sorrento Therapeutics Inc. (NASDAQ: SRNE), Pfizer Inc. (NYSE: PFE), Johnson & Johnson Services Inc., Merck & Co. Inc. (NYSE: MRK), bluebird bio-Inc. (NASDAQ: BLUE) and others.

Industry News and Updates:

• JW Therapeutics Announces NMPA Acceptance of Carteyva® Supplemental New Drug Application in Relapsed or Refractory Follicular Lymphoma Patients

27 February 2022 - JW Therapeutics (HKEx: 2126) announced that the National Medical Products Administration (NMPA) of China approved the supplemental New Drug Application (sNDA) for Carteyva® (relmacabtagene autoleucel injection) for the treatment of adult patients with relapsed or refractory follicular lymphoma (r/r FL). This is JW Therapeutics' second marketing application for Carteyva®, and it is expected to be the first cell therapy product approved in China for the treatment of r/r FL patients. In September 2020, the NMPA designated Carteyva® as a Breakthrough Therapy.

• CARsgen Therapeutics Opens New cGMP Facility in the United States for CAR T Production

Feb. 21, 2022, CARsgen Therapeutics Holdings Limited announced that its current Good Manufacturing Practices (cGMP) manufacturing facility located at the Research Triangle Park (RTP) in North Carolina, the United States of America ("The RTP Manufacturing Facility") has passed official local government inspections. CARsgen has received a Certificate of Compliance from Durham's City-County Inspections Department, allowing the company to move forward to clinical manufacturing.

• At ASH 2021, Novartis unveils T-ChargeTM, a next-generation CAR-T platform with first-in-human data.

13 December 2021 — Novartis introduced T-ChargeTM, the company's next-generation CAR-T platform, which will serve as the foundation for several new investigational CAR-T cell therapies in the Novartis pipeline.

What are the major Applications, Types, and Regions for the CAR-T Cell Therapy Market?

The market is segmented based on the type, applications, companies, and regions.

By Type, it is segmented into

• Axicabtagene Ciloleucel


• Tisagenlecleucel


• Brexucabtagene Autoleucel


• Lisocabtagene Maraleucel


• Idecabtagene Vicleucel


• Others

By Application, it is segmented into

• Hospitals


• Cancer Treatment Centers

CAR-T Cell Therapy Market Regional Analysis

North America is expected to dominate the market for chimeric antigen receptor (CAR)-T therapy treatment. This dominance can be attributed to the increased development and launch of clinical trials for cancer treatment, as well as the emerging biotechnological sector. Furthermore, rising cancer cases are fueling the region's market demand for cancer therapies. Furthermore, the region's leading players are focusing on expanding their global presence, which is boosting the CAR-T cell therapy market. Due to an increase in the number of global players cooperating and signing contracts with local players for CAR-T cell therapies in this region, Asia-Pacific is expected to show significant growth in the chimeric antigen receptor (CAR)-T therapy treatment market.

• North America
  
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East & Africa
  
  
  • Latin America
  
  
  
  

The CAR-T Cell Therapy Market describes the factors driving the global growth opportunities in upcoming years and highlights market channels. In addition, the report analyzes market size and share, trends, by geographic region, end-use type, and segment. It focuses extensively on revealing a detailed regional analysis. The Global CAR-T Cell Therapy Market report also conducted a PESTEL analysis of the industry to study the main influencing factors and entry barriers of the industry.

What is our CAR-T Cell Therapy Market report scope?

Scope of the Report covers CAR-T Cell Therapy Market with a detailed analysis of the overall scenario for the market. It also highlights the business participants’ environment in the global marketplace. This report also provides an overview of leading companies covering the latest successful marketing strategies, market contributions, current and historical background, and latest market happenings to help key organizations to grow and generate larger profits. Business players will greatly benefit from this CAR-T Cell Therapy Market analysis report as it has vital details to provide about regional markets and expected opportunities for the prediction time period 2022-2027. Growth between segments is used to understand the different growth factors that are expected to dominate the market as a whole and to develop strategies to differentiate between key applications and target markets. It further reveals how the worldwide market is working through efficient information graphics.

Report Attributes	Report Details
Report Title	CAR-T Cell Therapy Market - Global Growth, Trends and Forecast (2022 - 2027) By Types, By Application, By Regions, and By Key Players: Novartis AG (SWX: NOVN), Amgen Inc. (NASDAQ: AMGN), Fate Therapeutics (NASDAQ: FATE, Pfizer Inc. (NYSE: PFE)
Forecast Period 2022 to 2027 CAGR	CAGR of 31.5% over the forecast period (2022-2027)
By Type	Axicabtagene Ciloleucel Tisagenlecleucel Brexucabtagene Autoleucel Lisocabtagene Maraleucel Idecabtagene Vicleucel Others
By Application	Hospitals Cancer Treatment Centers
By Companies	Novartis AG, McKinsey & Company, Bristol-Myers Squibb Company, Gilead Sciences, Inc., Amgen Inc., Juno Therapeutics, Eli Lilly and Company, Fate Therapeutics, Sorrento Therapeutics, Inc., Pfizer Inc., Johnson & Johnson Services Inc., Merck & Co. Inc., bluebird bio-Inc.
Growth Drivers:	Increasing the number of Car T cell therapy product approvals Increase in cancer prevalence among the global population
Restraints & Challenges:	Challenges to developing car T cell therapy products
Regions Covered	North America Europe Asia-Pacific Rest of the World
Countries Covered	US Canada Germany France UK Italy Spain Rest of Europe China Japan India Australia South Korea Rest of Asia-Pacific Middle East & Africa Latin America
Base Year	2022
Historical Year	2017 to 2021
Forecast Year	2022 to 2027
Number of Pages	150
Customization Available	Yes, the report can be customized as per your needs

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Key Takeaways from this CAR-T Cell Therapy Report

• Evaluate CAR-T Cell Therapy market potential through analyzing growth rates (CAGR %), Volume (Units), and Value ($M) data given at the country level - for product types, end-use applications, and different industries verticals.


• Understand the different dynamics influencing the market - growth driving factors, specific challenges, and hidden opportunities.


• Get in-depth insights on your competitor’s performance – revenue, shares, business strategies, financial benchmarking, product benchmarking, SWOT analysis, and more.


• Analyze the sales and distribution channels across geographies to enhance top-line revenues.


• Understand the demanding supply chain with a deep dive on the value augmentation at each, in order to optimize value and bring efficiencies to your processes.


• Get a quick outlook on the CAR-T Cell Therapy market entropy – M&As, deals, partnerships, and product launches of all key players for the past 5 years.


• Evaluate the import-export statistics, supply-demand, and competitive landscape for more than the top 20 countries globally for the market.

Frequently Asked Questions

What is the study period of this market?

The CAR-T Cell Therapy Market is studied from 2017 - 2027.

What is the growth rate of the CAR-T Cell Therapy Market?

The CAR-T Cell Therapy Market is growing at a CAGR of 31.5% over the next 5 years.

Who are the key players in CAR-T Cell Therapy Market?

Novartis AG, McKinsey & Company, Bristol-Myers Squibb Company, Gilead Sciences Inc., Amgen Inc., Juno Therapeutics, Eli Lilly and Company, Fate Therapeutics, Sorrento Therapeutics, Inc., Pfizer Inc., Johnson & Johnson Services Inc., Merck & Co. Inc., bluebird bio-Inc.

What regions does this CAR-T Cell Therapy Market report cover?

North America (the United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, and Italy)

Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)

South America (Brazil, Argentina, Colombia, etc.)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

What are the significant types of CAR-T Cell Therapy Market?

Axicabtagene Ciloleucel, Tisagenlecleucel, Brexucabtagene Autoleucel, Lisocabtagene Maraleucel, Idecabtagene Vicleucel, Others

What are the major end-use applications of CAR-T Cell Therapy Market?

Hospitals, Cancer Treatment Centers

 

All our reports are custom made to your company’s needs to a certain extent, we do provide 5 free consulting hours along with the purchase of each report, and this will allow you to request any additional data to customize the report to your needs.